LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

8.35 0.85

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

8.17

Max

8.57

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M -20M
Pardavimai	5.9M 40M
Pelnas, tenkantis vienai akcijai	-0.19
Pelno marža	-49.569
Darbuotojai	184
EBITDA	16M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+185.8% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	153M 901M
Ankstesnė atidarymo kaina	7.5
Ankstesnė uždarymo kaina	8.35

Naujienos nuotaikos

By Acuity

50%

178 / 374 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-12-04 20:41; UTC

Uždarbis

Pagrindinės rinkos jėgos

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

2025-12-04 18:14; UTC

Įsigijimai, susijungimai, perėmimai

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

2025-12-04 17:43; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

2025-12-04 17:01; UTC

Uždarbis

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

2025-12-04 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

2025-12-04 23:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-04 21:54; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-12-04 21:54; UTC

Rinkos pokalbiai

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

2025-12-04 21:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-12-04 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-04 21:48; UTC

Rinkos pokalbiai

Scales Hits Mark With Earnings Guidance -- Market Talk

2025-12-04 21:37; UTC

Uždarbis

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

2025-12-04 21:36; UTC

Uždarbis

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

2025-12-04 20:15; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-12-04 20:15; UTC

Rinkos pokalbiai

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

2025-12-04 20:04; UTC

Rinkos pokalbiai

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

2025-12-04 19:54; UTC

Rinkos pokalbiai

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

2025-12-04 19:44; UTC

Įsigijimai, susijungimai, perėmimai

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

2025-12-04 19:44; UTC

Įsigijimai, susijungimai, perėmimai

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

2025-12-04 19:44; UTC

Įsigijimai, susijungimai, perėmimai

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

2025-12-04 19:33; UTC

Rinkos pokalbiai

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

2025-12-04 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

2025-12-04 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

2025-12-04 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

2025-12-04 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

2025-12-04 18:58; UTC

Rinkos pokalbiai

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

2025-12-04 17:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-12-04 17:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-12-04 16:41; UTC

Rinkos pokalbiai

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

2025-12-04 16:33; UTC

Rinkos pokalbiai

Uždarbis

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

185.8% į viršų

12 mėnesių prognozė

Vidutinis 23.75 USD 185.8%

Aukščiausias 34 USD

Žemiausias 16 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

178 / 374 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.